Skip to content
← Back to ingredients

Ritlecitinib

Also known as: Litfulo

Strong EvidencePharmaceuticalAlopecia Areata

FDA-approved oral JAK3/TEC inhibitor for alopecia areata in patients 12 and older.

Regrowth Potential60%
Long-Term Viability75%

Mechanism of Action

Ritlecitinib irreversibly inhibits JAK3 and the TEC family of kinases. JAK3 inhibition blocks IL-15 and IL-21 signaling critical for cytotoxic CD8+ T cell activation that attacks hair follicles in alopecia areata. TEC kinase inhibition provides additional suppression of T cell and NK cell responses.

Unlock Premium Content

Get full access to in-depth analyses, cited studies, premium articles, and AI chat.

$12/mo

View pricing